Novo Nordisk's CagriSema Delivers 12.4% Weight Loss, Beats Lilly's Tirzepatide in Trial
Bengaluru: Novo Nordisk said on Monday its next-generation experimental drug, CagriSema, delivered an estimated average weight loss of 12.4% in a late-stage trial in patients with diabetes, outperforming Eli Lilly's rival drug.
It has been seen as a successor to Novo's weight loss drug, Wegovy, which faces patent expiries after 2030.
CagriSema is a weekly injection combining cagrilintide, which mimics pancreatic hormone amylin, and semaglutide, the active ingredient in Wegovy. Novo said the drug also demonstrated non-inferior blood sugar reduction compared to Lilly's tirzepatide.
In a head-to-head trial earlier this year, the drug had fallen short of Lilly's Zepbound on weight loss, marking a setback for the Danish drugmaker.
In the late-stage study, a 1 mg dose of Novo's drug CagriSema was superior to Lilly's tirzepatide at 5 mg for weight loss, the company said on Monday.
Lilly's tirzepatide, which is the active ingredient in its diabetes drug Mounjaro and obesity drug Zepbound, showed weight loss of 9.1%.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.